Somatropin - CJ HealthCare Corporation

Drug Profile

Somatropin - CJ HealthCare Corporation

Alternative Names: ALT-P1; CJ-40002; hGH-NexP; Recombinant human growth hormone - CJ Healthcare

Latest Information Update: 18 May 2017

Price : $50

At a glance

  • Originator CJ Corporation
  • Class Growth hormones; Hormonal replacements
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Somatotropin deficiency

Most Recent Events

  • 26 Apr 2017 Alteogen and Cristalia sign a letter of intent to co-promote and co-develop somatropin in Latin America for Somatropin deficiency
  • 26 Apr 2017 Alteogen files an IND application with the Korea Food and Drug Administration in Korea for Somatropin deficiency
  • 29 Jul 2016 Final safety and pharmacokinetics data from a phase I trial in healthy volunteers presented at The 98th Annual Meeting of the Endocrine Society (ENDO-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top